Clinical Trial Update: A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD [Phase 3]

View source ↗

Summary

Phase 3 24-week study results for the inhaled combination of fluticasone furoate and vilanterol in subjects of Asian ancestry with chronic obstructive pulmonary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone furoate/vilanterol inhalation powder (fluticasone furoate/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-01-28